reviewed april 2026|next review october 2026|88 physicians psi has verified|137453 published studies
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for neurodegenerative disease that produced up to 12.8% weight loss in Phase II obesity trials, with the primary safety concern being dose-dependent heart rate elevation.
Evidence landscape: 137453 published studies
137,453 published items (inflated by broad monoamine query). 40 human studies and 127 animal studies.
- 40 Human
- 127 Animal
- 33 Reviews
- 137253 Other research
Not FDA-approved. Phase II completed with strong weight loss data. Phase III conducted outside the US (Mexico). The combination formulation with metoprolol is in development. No US or EU regulatory submission has been filed.
Not available through standard pharmacies. The compound is in clinical development. Availability outside clinical trials varies by jurisdiction.
Triple monoamine reuptake inhibitor. Entirely different mechanism from GLP-1 drugs (brain monoamine signaling versus gut hormones). Originally developed for Alzheimer's and Parkinson's disease, redirected to obesity after dramatic weight loss as a side effect.
PSI Assessment
Originally developed for Alzheimer's and Parkinson's disease, tesofensine produced dramatic weight loss as a side effect in neurodegenerative trials, redirecting its development to obesity. Phase II trials showed up to 12.8% body weight reduction at the highest dose, a result that was competitive with early GLP-1 data at the time. The mechanism is unique: triple reuptake inhibition of serotonin, norepinephrine, and dopamine simultaneously increases satiety, energy expenditure, and reduces food reward. The heart rate increase from norepinephrine reuptake inhibition is managed by co-formulation with the beta-blocker metoprolol. The compound is advancing through Phase III in the combination formulation.
Up to 12.8% weight loss in Phase II. Triple monoamine mechanism distinct from every GLP-1 drug. Heart rate concern managed by metoprolol co-formulation.
The mechanism is triple monoamine reuptake inhibition. By increasing serotonin (satiety), norepinephrine (energy expenditure), and dopamine (reduced food reward) simultaneously, tesofensine addresses appetite, metabolic rate, and hedonic eating through a mechanism entirely distinct from GLP-1 agonists. The trade-off is that norepinephrine reuptake inhibition also increases heart rate, which is managed by co-formulation with metoprolol.
What the evidence supports
Phase II trials demonstrate dose-dependent weight loss up to 12.8% at the highest dose. Triple monoamine reuptake inhibition is pharmacologically distinct from every approved obesity medication. Increased energy expenditure is documented alongside appetite suppression. The metoprolol combination manages the heart rate increase.
What is not yet established
Phase III efficacy and safety with the metoprolol combination. Whether the cardiovascular risk profile is acceptable at scale. How tesofensine compares to now-available GLP-1 drugs that were not available when Phase II was conducted. Long-term weight maintenance.
Research Evidence
The findings below cover what Phase II data established, how the mechanism compares to GLP-1 drugs, and where the cardiovascular safety question currently stands.
Evidence by condition
Evidence dimensions across tesofensine's investigated applications. Obesity has Phase II human data with replication. Appetite suppression is well-characterized. Neurodegenerative applications are a failed indication.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Obesity | ||||
| Appetite Suppression | ||||
| Neurodegenerative Disease |
Phase II TIPO trials demonstrated dose-dependent weight loss of 6.7%, 11.3%, and 12.8% at 0.25mg, 0.5mg, and 1.0mg doses respectively over 24 weeks. The highest dose was competitive with early GLP-1 agonist data available at the time.
The GLP-1 landscape has changed substantially since these Phase II trials. Semaglutide and tirzepatide now show 15-22% weight loss. Tesofensine's competitive position depends on the unique mechanism and the metoprolol combination safety profile.
The triple monoamine mechanism is pharmacologically distinct from every approved obesity medication. Serotonin increases satiety, norepinephrine increases energy expenditure, and dopamine reduces the reward value of food.
This mechanistic distinctness is both the advantage (potential combination with GLP-1 drugs) and the challenge (cardiovascular safety profile differs from GLP-1 class).
Heart rate increases of 5-10 beats per minute were observed at therapeutic doses, driven by norepinephrine reuptake inhibition. The metoprolol co-formulation is designed to manage this cardiovascular effect.
Whether the metoprolol combination produces an acceptable cardiovascular profile at scale is the key safety question. Phase III data with the combination is needed.
40 Human|127 Animal|33 Reviews
View all 137453 indexed studiesHow Tesofensine Works
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine simultaneously.
Tesofensine increases three brain chemicals that control appetite and energy: serotonin (satiety), norepinephrine (energy expenditure), and dopamine (reward and motivation). By increasing all three, it reduces hunger, increases calories burned, and reduces the reward drive for eating. The trade-off is that norepinephrine also increases heart rate.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Tesofensine inhibits presynaptic reuptake of 5-HT, NE, and DA. It has higher affinity for NE and DA transporters than for SERT. The triple reuptake mechanism produces appetite suppression, increased energy expenditure, and reduced food reward. Heart rate increases are mediated by peripheral NE effects and are managed with metoprolol co-administration.
What is Tesofensine being studied for?
Researchers are studying Tesofensine across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Tesofensine overall. This means a compound can have human studies for one condition but only animal data for another.
Obesity
·Human TrialsPhase II trials showed up to 12.8% weight loss at the highest dose. The combination with metoprolol is advancing through development.
Limitations: Phase III with metoprolol combination is needed. The cardiovascular profile (heart rate and blood pressure increases) is a significant safety concern. Comparison to now-available GLP-1 drugs is unknown.
Appetite Suppression
·Animal StudiesThe triple monoamine mechanism produces robust appetite reduction through three complementary pathways: serotonin for satiety, dopamine for reduced food reward, and norepinephrine for increased energy expenditure.
Limitations: Whether the triple mechanism offers advantages over selective approaches is debated.
Neurodegenerative Disease
·PreclinicalFailed indication. Tesofensine was originally developed for Alzheimer's and Parkinson's disease but failed to show cognitive or motor benefit in Phase II/III trials despite the monoamine mechanism.
Limitations: Neurodegenerative applications are abandoned. The weight loss observed as a side effect redirected development toward obesity.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Phase III conducted outside the US (Mexico). No US or EU regulatory submission.
Availability: Not available through standard pharmacies. Clinical development ongoing with the metoprolol combination formulation.
Class context: Heart rate and blood pressure increases from norepinephrine reuptake inhibition are the primary safety concern. The metoprolol combination is designed to manage this. Other reported side effects include insomnia, dry mouth, and constipation.
Tesofensine increases heart rate and blood pressure due to norepinephrine reuptake inhibition. This is managed by co-administration with metoprolol (a beta-blocker). The combination is being evaluated in Phase III. Other reported side effects include insomnia, dry mouth, and constipation. Tesofensine is investigational and not FDA-approved.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Tesofensine discussion.
Comparison and Related Research
Tesofensine is most often compared with GLP-1 agonists and other centrally-acting obesity medications that work through different mechanisms.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The TIPO-1 Phase 2 trial, the pivotal study for tesofensine, evaluated three doses of the triple monoamine reuptake inhibitor in adults with obesity over 24 weeks. The highest dose produced approximately 12.8 kg of weight loss (roughly 10% of body weight), making it one of the largest weight reductions observed in an obesity drug trial at that time. Weight loss was accompanied by improvements in body composition and quality of life.Astrup A et al., 2008 in Lancet. View on PubMed
- 2.Mechanistic study investigating how tesofensine produces weight loss. The study found that tesofensine primarily reduces body weight through appetite suppression rather than increased energy expenditure. Treatment was associated with reduced hunger ratings, decreased food intake at ad libitum meals, and a shift in fat oxidation, providing insight into the pharmacological basis of the observed clinical weight loss.Sjodin A et al., 2010 in Int J Obes (Lond). View on PubMed
- 3.Preclinical study characterizing the receptor-level mechanism of tesofensine-induced appetite suppression. By blocking reuptake of serotonin, norepinephrine, and dopamine simultaneously, tesofensine increases signaling through alpha-1 adrenergic and dopamine D1 receptor pathways in brain circuits that regulate feeding behavior, producing stronger appetite reduction than targeting any single monoamine system alone.Axel AM et al., 2010 in Neuropsychopharmacology. View on PubMed
- 4.Analysis of appetite and satiety measures from the TIPO-1 trial. Tesofensine significantly reduced hunger, desire to eat, and prospective food consumption while increasing fullness ratings, confirming that appetite suppression is the primary mechanism driving weight loss. The appetite effects were dose-dependent, consistent with the dose-dependent weight loss observed in the main trial.Gilbert JA et al., 2012 in Obesity (Silver Spring). View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.